Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial.
Sands BE, Rubin DT, Loftus EV Jr, Wolf DC, Panaccione R, Colombel JF, Dignass A, Regueiro M, Vermeire S, Afzali A, Lawlor G, Ahmad HA, Wu H, Osterman MT, Jain A, D'Haens G.
Sands BE, et al. Among authors: loftus ev jr.
Am J Gastroenterol. 2025 Jan 8. doi: 10.14309/ajg.0000000000003310. Online ahead of print.
Am J Gastroenterol. 2025.
PMID: 39773524